Skip to main content
Top
Published in: Abdominal Radiology 4/2016

01-04-2016 | Pictorial essay

Hepatic imaging following intra-arterial embolotherapy

Authors: Joseph Ralph Kallini, Frank H. Miller, Ahmed Gabr, Riad Salem, Robert J. Lewandowski

Published in: Abdominal Radiology | Issue 4/2016

Login to get access

Abstract

Purpose

To discuss guidelines and salient imaging findings of solid tumors treated with common intra-arterial procedures used in interventional oncology.

Methods

A meticulous literature search of PubMed-indexed articles was conducted. Key words included “imaging + embolization,” “imaging + TACE,” “imaging + radioembolization,” “imaging + Y90,” “mRECIST,” and “EASL.” Representative post-treatment cross-sectional images were obtained from past cases in this institution.

Results

Intra-arterial therapy (IAT) in interventional oncology includes bland embolization, chemoembolization, and radioembolization. Solid tumors of the liver are the primary focus of these procedures. Cross-sectional CT and/or MR are the main modalities used to image tumors after treatment. Traditional size-based response criteria (WHO and RECIST) alone are of limited utility in determining response to IAT; tumoral necrosis and enhancement must be considered. Specifically for HCC, the EASL and mRECIST guidelines are becoming widely adopted response criteria to assess these factors. DWI, FDG-PET, and CEUS are modalities that play an adjunctive but controversial role.

Conclusions

Radiologists must be aware that the different forms of intra-arterial therapy yield characteristic findings on cross-sectional imaging. Knowledge of these findings is integral to accurate assessment of tumor response and progression.
Literature
5.
8.
go back to reference SIRS-Spheres Yttrium-90 microspheres package insert. Singapore Science Park SSM. SIRS-Spheres Yttrium-90 microspheres package insert. Singapore Science Park SSM.
9.
go back to reference TheraSphere Yttrium-90 microspheres package insert. Kanata CMN. TheraSphere Yttrium-90 microspheres package insert. Kanata CMN.
10.
go back to reference Hickey R, Mulcahy MF, Lewandowski RJ, et al. (2014) Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys 88(5):1025–1031. doi:10.1016/j.ijrobp.2013.12.040 CrossRefPubMed Hickey R, Mulcahy MF, Lewandowski RJ, et al. (2014) Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys 88(5):1025–1031. doi:10.​1016/​j.​ijrobp.​2013.​12.​040 CrossRefPubMed
15.
go back to reference Wald C, Russo MW, Heimbach JK, et al. (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266(2):376–382. doi:10.1148/radiol.12121698 CrossRefPubMed Wald C, Russo MW, Heimbach JK, et al. (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266(2):376–382. doi:10.​1148/​radiol.​12121698 CrossRefPubMed
19.
go back to reference Halappa VG, Bonekamp S, Corona-Villalobos CP, et al. (2012) Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology 264(1):285–294. doi:10.1148/radiol.12112142 CrossRefPubMed Halappa VG, Bonekamp S, Corona-Villalobos CP, et al. (2012) Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology 264(1):285–294. doi:10.​1148/​radiol.​12112142 CrossRefPubMed
21.
go back to reference Barabasch A, Kraemer NA, Ciritsis A, et al. (2015) Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization. Investig Radiol 50(6):409–415. doi:10.1097/rli.0000000000000144 CrossRef Barabasch A, Kraemer NA, Ciritsis A, et al. (2015) Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization. Investig Radiol 50(6):409–415. doi:10.​1097/​rli.​0000000000000144​ CrossRef
22.
go back to reference Li Z, Bonekamp S, Halappa VG, et al. (2012) Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization. Radiology 264(1):97–109. doi:10.1148/radiol.12112161 CrossRefPubMed Li Z, Bonekamp S, Halappa VG, et al. (2012) Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization. Radiology 264(1):97–109. doi:10.​1148/​radiol.​12112161 CrossRefPubMed
24.
go back to reference Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S, et al. (2013) Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival. Radiology 266(2):502–513. doi:10.1148/radiol.12120495 CrossRefPubMed Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S, et al. (2013) Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival. Radiology 266(2):502–513. doi:10.​1148/​radiol.​12120495 CrossRefPubMed
27.
go back to reference El-Gazzaz G, Sourianarayanane A, Menon KV, et al. (2013) Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies. Hepatobiliary Pancreat Dis Int 12(1):34–41CrossRefPubMed El-Gazzaz G, Sourianarayanane A, Menon KV, et al. (2013) Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies. Hepatobiliary Pancreat Dis Int 12(1):34–41CrossRefPubMed
28.
go back to reference Gulec SA, Suthar RR, Barot TC, Pennington K (2011) The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging 38(7):1289–1295. doi:10.1007/s00259-011-1758-4 CrossRefPubMed Gulec SA, Suthar RR, Barot TC, Pennington K (2011) The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging 38(7):1289–1295. doi:10.​1007/​s00259-011-1758-4 CrossRefPubMed
29.
go back to reference Sabet A, Meyer C, Aouf A, et al. (2015) Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. Eur J Nucl Med Mol Imaging 42(3):370–376. doi:10.1007/s00259-014-2935-z CrossRefPubMed Sabet A, Meyer C, Aouf A, et al. (2015) Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. Eur J Nucl Med Mol Imaging 42(3):370–376. doi:10.​1007/​s00259-014-2935-z CrossRefPubMed
31.
go back to reference Edalat F, Camacho JC, Kokabi N, et al. (2015) Standardized added metabolic activity (SAM) predicts survival after intra-arterial resin-based 90Y radioembolization therapy in unresectable chemorefractory metastatic colorectal cancer to the liver. Clin Nucl Med . doi:10.1097/rlu.0000000000000991 Edalat F, Camacho JC, Kokabi N, et al. (2015) Standardized added metabolic activity (SAM) predicts survival after intra-arterial resin-based 90Y radioembolization therapy in unresectable chemorefractory metastatic colorectal cancer to the liver. Clin Nucl Med . doi:10.​1097/​rlu.​0000000000000991​
32.
go back to reference Bagni O, Filippi L, Schillaci O (2015) The role of (18)F-FDG positron emission tomography in the follow-up of liver tumors treated with (90)Yttrium radioembolization. Am J Nucl Med Mol Imaging 5(3):220–232PubMedPubMedCentral Bagni O, Filippi L, Schillaci O (2015) The role of (18)F-FDG positron emission tomography in the follow-up of liver tumors treated with (90)Yttrium radioembolization. Am J Nucl Med Mol Imaging 5(3):220–232PubMedPubMedCentral
33.
go back to reference Hartenbach M, Weber S, Albert NL, et al. (2015) Evaluating treatment response of radioembolization in intermediate-stage hepatocellular carcinoma patients using 18F-fluoroethylcholine PET/CT. J Nucl Med 56(11):1661–1666. doi:10.2967/jnumed.115.158758 CrossRefPubMed Hartenbach M, Weber S, Albert NL, et al. (2015) Evaluating treatment response of radioembolization in intermediate-stage hepatocellular carcinoma patients using 18F-fluoroethylcholine PET/CT. J Nucl Med 56(11):1661–1666. doi:10.​2967/​jnumed.​115.​158758 CrossRefPubMed
34.
go back to reference Khan MA, Combs CS, Brunt EM, et al. (2000) Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32(5):792–797CrossRefPubMed Khan MA, Combs CS, Brunt EM, et al. (2000) Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32(5):792–797CrossRefPubMed
37.
go back to reference Kim HJ, Kim TK, Kim PN, et al. (2006) Assessment of the therapeutic response of hepatocellular carcinoma treated with transcatheter arterial chemoembolization: comparison of contrast-enhanced sonography and 3-phase computed tomography. J Ultrasound Med 25(4):477–486PubMed Kim HJ, Kim TK, Kim PN, et al. (2006) Assessment of the therapeutic response of hepatocellular carcinoma treated with transcatheter arterial chemoembolization: comparison of contrast-enhanced sonography and 3-phase computed tomography. J Ultrasound Med 25(4):477–486PubMed
39.
go back to reference Bartolotta TV, Taibbi A, Matranga D, Midiri M, Lagalla R (2015) 3D versus 2D contrast-enhanced sonography in the evaluation of therapeutic response of hepatocellular carcinoma after locoregional therapies: preliminary findings. Radiol Med 120(8):695–704. doi:10.1007/s11547-015-0514-4 CrossRefPubMed Bartolotta TV, Taibbi A, Matranga D, Midiri M, Lagalla R (2015) 3D versus 2D contrast-enhanced sonography in the evaluation of therapeutic response of hepatocellular carcinoma after locoregional therapies: preliminary findings. Radiol Med 120(8):695–704. doi:10.​1007/​s11547-015-0514-4 CrossRefPubMed
40.
go back to reference Quaia E, Lorusso A, Grisi G, Stacul F, Cova MA (2012) The role of CEUS in the characterization of hepatocellular nodules detected during the US surveillance program-current practices in Europe. Ultraschall Med 33(Suppl 1):S48–56. doi:10.1055/s-0032-1312899 PubMed Quaia E, Lorusso A, Grisi G, Stacul F, Cova MA (2012) The role of CEUS in the characterization of hepatocellular nodules detected during the US surveillance program-current practices in Europe. Ultraschall Med 33(Suppl 1):S48–56. doi:10.​1055/​s-0032-1312899 PubMed
41.
go back to reference Moschouris H, Malagari K, Papadaki MG, et al. (2014) mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization. Diagn Interv Radiol 20(2):136–142. doi:10.5152/dir.2013.13282 PubMedPubMedCentral Moschouris H, Malagari K, Papadaki MG, et al. (2014) mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization. Diagn Interv Radiol 20(2):136–142. doi:10.​5152/​dir.​2013.​13282 PubMedPubMedCentral
42.
go back to reference Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Instit 92(3):205–216CrossRef Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Instit 92(3):205–216CrossRef
44.
go back to reference Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430CrossRefPubMed Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430CrossRefPubMed
45.
46.
go back to reference Shuster A, Huynh TJ, Rajan DK, et al. (2013) Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer. J Vasc Interv Radiol 24(6):805–812. doi:10.1016/j.jvir.2013.01.499 CrossRefPubMed Shuster A, Huynh TJ, Rajan DK, et al. (2013) Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer. J Vasc Interv Radiol 24(6):805–812. doi:10.​1016/​j.​jvir.​2013.​01.​499 CrossRefPubMed
47.
go back to reference Donati OF, Do RK, Hotker AM, et al. (2015) Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma. Eur Radiol 25(9):2779–2788. doi:10.1007/s00330-015-3677-4 CrossRefPubMed Donati OF, Do RK, Hotker AM, et al. (2015) Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma. Eur Radiol 25(9):2779–2788. doi:10.​1007/​s00330-015-3677-4 CrossRefPubMed
50.
go back to reference Odisio BC, Galastri F, Avritscher R, et al. (2014) Hepatocellular carcinomas within the Milan criteria: predictors of histologic necrosis after drug-eluting beads transarterial chemoembolization. Cardiovasc Interv Radiol 37(4):1018–1026. doi:10.1007/s00270-013-0759-z CrossRef Odisio BC, Galastri F, Avritscher R, et al. (2014) Hepatocellular carcinomas within the Milan criteria: predictors of histologic necrosis after drug-eluting beads transarterial chemoembolization. Cardiovasc Interv Radiol 37(4):1018–1026. doi:10.​1007/​s00270-013-0759-z CrossRef
51.
go back to reference Prajapati HJ, Spivey JR, Hanish SI, et al. (2013) mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 24(4):965–973. doi:10.1093/annonc/mds605 CrossRefPubMed Prajapati HJ, Spivey JR, Hanish SI, et al. (2013) mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 24(4):965–973. doi:10.​1093/​annonc/​mds605 CrossRefPubMed
52.
go back to reference Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A, et al. (2015) Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology 62(4):1111–1121. doi:10.1002/hep.27915 CrossRefPubMed Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A, et al. (2015) Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology 62(4):1111–1121. doi:10.​1002/​hep.​27915 CrossRefPubMed
54.
go back to reference Tacher V, Lin M, Duran R, et al. (2015) Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach. Radiology . doi:10.1148/radiol.2015142951 Tacher V, Lin M, Duran R, et al. (2015) Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach. Radiology . doi:10.​1148/​radiol.​2015142951
60.
go back to reference Kamel IR, Liapi E, Reyes DK, et al. (2009) Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 250(2):466–473. doi:10.1148/radiol.2502072222 CrossRefPubMed Kamel IR, Liapi E, Reyes DK, et al. (2009) Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 250(2):466–473. doi:10.​1148/​radiol.​2502072222 CrossRefPubMed
61.
go back to reference Yoon HM, Kim JH, Kim EJ, et al. (2013) Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort. J Vasc Interv Radiol 24(11):1639–1646. doi:10.1016/j.jvir.2013.06.017 CrossRefPubMed Yoon HM, Kim JH, Kim EJ, et al. (2013) Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort. J Vasc Interv Radiol 24(11):1639–1646. doi:10.​1016/​j.​jvir.​2013.​06.​017 CrossRefPubMed
64.
go back to reference Vesselle G, Quirier-Leleu C, Velasco S, et al. (2015) Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. Eur Radiol . doi:10.1007/s00330-015-3982-y PubMed Vesselle G, Quirier-Leleu C, Velasco S, et al. (2015) Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. Eur Radiol . doi:10.​1007/​s00330-015-3982-y PubMed
66.
go back to reference Kim HC, Kim AY, Han JK, et al. (2002) Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images. Radiology 225(3):773–780. doi:10.1148/radiol.2253011346 CrossRefPubMed Kim HC, Kim AY, Han JK, et al. (2002) Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images. Radiology 225(3):773–780. doi:10.​1148/​radiol.​2253011346 CrossRefPubMed
68.
go back to reference Kim DJ, Clark PJ, Heimbach J, et al. (2014) Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transpl 14(6):1383–1390. doi:10.1111/ajt.12684 CrossRef Kim DJ, Clark PJ, Heimbach J, et al. (2014) Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transpl 14(6):1383–1390. doi:10.​1111/​ajt.​12684 CrossRef
69.
go back to reference Yeo DM, Choi JI, Lee YJ, et al. (2014) Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads. J Comput Assist Tomogr 38(3):391–397. doi:10.1097/rct.0000000000000070 CrossRefPubMed Yeo DM, Choi JI, Lee YJ, et al. (2014) Comparison of RECIST, mRECIST, and choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads. J Comput Assist Tomogr 38(3):391–397. doi:10.​1097/​rct.​0000000000000070​ CrossRefPubMed
70.
go back to reference Hyun D, Shin SW, Cho SK, et al. (2014) Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. Acta Radiol . doi:10.1177/0284185114560937 Hyun D, Shin SW, Cho SK, et al. (2014) Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. Acta Radiol . doi:10.​1177/​0284185114560937​
71.
go back to reference Kloeckner R, Otto G, Biesterfeld S, et al. (2010) MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiov Interv Radiol 33(3):532–540. doi:10.1007/s00270-009-9728-y CrossRef Kloeckner R, Otto G, Biesterfeld S, et al. (2010) MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiov Interv Radiol 33(3):532–540. doi:10.​1007/​s00270-009-9728-y CrossRef
72.
go back to reference Imai N, Katano Y, Kuzuya T, et al. (2013) An increase in lesion density can predict lower local recurrence after transarterial chemoembolization in patients with hepatocellular carcinoma. Hepato-gastroenterology 60(125):965–970. doi:10.5754/hge121229 PubMed Imai N, Katano Y, Kuzuya T, et al. (2013) An increase in lesion density can predict lower local recurrence after transarterial chemoembolization in patients with hepatocellular carcinoma. Hepato-gastroenterology 60(125):965–970. doi:10.​5754/​hge121229 PubMed
74.
go back to reference Lim HK, Han JK (2002) Hepatocellular carcinoma: evaluation of therapeutic response to interventional procedures. Abdom Imaging 27(2):168–179CrossRefPubMed Lim HK, Han JK (2002) Hepatocellular carcinoma: evaluation of therapeutic response to interventional procedures. Abdom Imaging 27(2):168–179CrossRefPubMed
75.
go back to reference Wang Z, Chen R, Duran R, et al. (2015) Intraprocedural 3D quantification of lipiodol deposition on cone-beam CT predicts tumor response after transarterial chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Interv Radiol . doi:10.1007/s00270-015-1129-9 Wang Z, Chen R, Duran R, et al. (2015) Intraprocedural 3D quantification of lipiodol deposition on cone-beam CT predicts tumor response after transarterial chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Interv Radiol . doi:10.​1007/​s00270-015-1129-9
78.
go back to reference Mannelli L, Kim S, Hajdu CH, et al. (2009) Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 193(4):1044–1052. doi:10.2214/ajr.08.1461 CrossRefPubMed Mannelli L, Kim S, Hajdu CH, et al. (2009) Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 193(4):1044–1052. doi:10.​2214/​ajr.​08.​1461 CrossRefPubMed
79.
go back to reference Shinagawa Y, Sakamoto K, Fujimitsu R, et al. (2012) Pseudolesion of the liver on gadoxetate disodium-enhanced MR images obtained after transarterial chemoembolization for hepatocellular carcinoma: clinicoradiologic correlation. AJR Am J Roentgenol 199(5):1010–1017. doi:10.2214/ajr.11.8204 CrossRefPubMed Shinagawa Y, Sakamoto K, Fujimitsu R, et al. (2012) Pseudolesion of the liver on gadoxetate disodium-enhanced MR images obtained after transarterial chemoembolization for hepatocellular carcinoma: clinicoradiologic correlation. AJR Am J Roentgenol 199(5):1010–1017. doi:10.​2214/​ajr.​11.​8204 CrossRefPubMed
81.
go back to reference Kokabi N, Camacho JC, Xing M, et al. (2015) Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: a pilot study. J Magn Reson Imaging 42(4):981–989. doi:10.1002/jmri.24845 CrossRefPubMed Kokabi N, Camacho JC, Xing M, et al. (2015) Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: a pilot study. J Magn Reson Imaging 42(4):981–989. doi:10.​1002/​jmri.​24845 CrossRefPubMed
82.
go back to reference Corona-Villalobos CP, Halappa VG, Geschwind JF, et al. (2015) Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. Eur Radiol 25(2):380–390. doi:10.1007/s00330-014-3412-6 CrossRefPubMedPubMedCentral Corona-Villalobos CP, Halappa VG, Geschwind JF, et al. (2015) Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. Eur Radiol 25(2):380–390. doi:10.​1007/​s00330-014-3412-6 CrossRefPubMedPubMedCentral
84.
go back to reference Shaw CM, Eisenbrey JR, Lyshchik A, et al. (2015) Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: a prospective study. J Ultrasound Med 34(5):859–867. doi:10.7863/ultra.34.5.859 CrossRefPubMed Shaw CM, Eisenbrey JR, Lyshchik A, et al. (2015) Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: a prospective study. J Ultrasound Med 34(5):859–867. doi:10.​7863/​ultra.​34.​5.​859 CrossRefPubMed
86.
go back to reference Brown DB, Cardella JF, Sacks D, et al. (2009) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 20(7 Suppl):S219–S226.e211–210. doi:10.1016/j.jvir.2009.04.033 CrossRefPubMed Brown DB, Cardella JF, Sacks D, et al. (2009) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 20(7 Suppl):S219–S226.e211–210. doi:10.​1016/​j.​jvir.​2009.​04.​033 CrossRefPubMed
87.
go back to reference Li H, Li N, Xiang Q, Zhou Y (2014) Value of hepatic diffusion-weighted magnetic resonance imaging in evaluating liver fibrosis following transarterial chemoembolization with low doses of chemotherapy. Exp Ther Med 8(2):642–646. doi:10.3892/etm.2014.1767 PubMedPubMedCentral Li H, Li N, Xiang Q, Zhou Y (2014) Value of hepatic diffusion-weighted magnetic resonance imaging in evaluating liver fibrosis following transarterial chemoembolization with low doses of chemotherapy. Exp Ther Med 8(2):642–646. doi:10.​3892/​etm.​2014.​1767 PubMedPubMedCentral
89.
go back to reference Sato K, Lewandowski RJ, Bui JT, et al. (2006) Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiov Interv Radiol 29(4):522–529. doi:10.1007/s00270-005-0171-4 CrossRef Sato K, Lewandowski RJ, Bui JT, et al. (2006) Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiov Interv Radiol 29(4):522–529. doi:10.​1007/​s00270-005-0171-4 CrossRef
90.
91.
go back to reference Riaz A, Kulik L, Lewandowski RJ, et al. (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49(4):1185–1193. doi:10.1002/hep.22747 CrossRefPubMed Riaz A, Kulik L, Lewandowski RJ, et al. (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49(4):1185–1193. doi:10.​1002/​hep.​22747 CrossRefPubMed
94.
go back to reference Rhee TK, Naik NK, Deng J, et al. (2008) Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 19(8):1180–1186. doi:10.1016/j.jvir.2008.05.002 CrossRefPubMed Rhee TK, Naik NK, Deng J, et al. (2008) Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 19(8):1180–1186. doi:10.​1016/​j.​jvir.​2008.​05.​002 CrossRefPubMed
96.
Metadata
Title
Hepatic imaging following intra-arterial embolotherapy
Authors
Joseph Ralph Kallini
Frank H. Miller
Ahmed Gabr
Riad Salem
Robert J. Lewandowski
Publication date
01-04-2016
Publisher
Springer US
Published in
Abdominal Radiology / Issue 4/2016
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-016-0639-5

Other articles of this Issue 4/2016

Abdominal Radiology 4/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.